Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Former U.S. Navy Chief Petty Office Bree Kuhn gunned down her husband, Collin Turner, in the couple's Florida home while he ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

The study found that Sogroya was more effective than a daily growth hormone in children with NS2. The results of a sub-study on Turner syndrome are expected to be released later this year. Novo ...

This initiative aligns with Sandoz’s ongoing efforts to support Egypt’s Vision 2030 and local healthcare authorities’ ...

Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, ...

A man charged with murder in the death of his roommate allegedly admitted to dismembering her after beating her with a ...

Internet sleuths are fueling speculation about a serial killer in New England after the discoveries of several sets of human ...